Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Oncology
- Publicado em
- 27 mai 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Sara Lonardi, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto et al.
Descritores MeSH
- Rectal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin
- Leucovorin
- Fluorouracil
- Humans
- Organoplatinum Compounds
- Bevacizumab
Veja também
Estudos relacionados
- Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
- Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
- First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial
- QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC